Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

References

• Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen J W, Ratei R, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia 1996; 10: 957–963
   PubMed Web of Science ®Google Scholar
• Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. Blood 1996; 87: 3135–3142
   PubMed Web of Science ®Google Scholar
• Radich J P. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 21–36
   PubMed Web of Science ®Google Scholar
• Bartram C R, de Klein A, Hagemeijer A, Van Agthoven T, Geurts Van Kessal A HM, Bootsma D, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277–280
   PubMed Web of Science ®Google Scholar
• Chan L C, Karhi K K, Rayter S I, Heisterkamp N, Eridani S, Powles R, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987; 325: 635–637
   PubMed Web of Science ®Google Scholar
• Maurer J, Janssen J WG, Thiel E, Van Denderen J, Ludwig W D, Aydemir U, et al. Detection of chimeric Bcr-Abl genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991; 337: 1055–1058
   PubMed Web of Science ®Google Scholar
• Lugo T G, Pendergast A M, Muler A J, Witte O N. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 1990; 247: 1079–1083
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron J M, Rigal-Huguet F, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive leukemia – results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357–2366
   PubMed Web of Science ®Google Scholar
• Gleissner B, Gökbuget N, Bartram C R, Janssen B, Rieder H, Janssen J WG, et al. Leading prognostic relevance of the Bcr-Abl translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536–1543
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H M. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Rieder H, Ludwig W D, Gassmann W, Maurer J, Janssen J WG, Gökbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996; 95: 678–691
   PubMed Web of Science ®Google Scholar
• Secker-Walker L M, Prentice H G, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trail UKALL XA. Br J Haematol 1997; 96: 601–610
   PubMed Web of Science ®Google Scholar
• Westbrook C A, Hooberman A L, Spino C, Dodge R K, Larson R A, Davey F, et al. Clinical significance of the Bcr-Abl fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762. Blood 1992; 80: 2983–2990
   PubMed Web of Science ®Google Scholar
• Götz G, Weh H J, Walter T A, Kuse R, Kolbe K, Dolken G, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Haematol 1992; 64: 97–100
   PubMed Web of Science ®Google Scholar
• Preti H A, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian H M. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994; 97: 60–65
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna M L, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871
   PubMed Web of Science ®Google Scholar
• Thomas X, Thiebaut A, Olteanu N, Danaïla C, Charrin C, Archimbaud E, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treament outcome. Hematol Cell Ther 1998; 40: 119–128
   PubMedGoogle Scholar
• Kantarjian H M, O'Brien S, Smith T L, Cortes J, Giles F J, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561
   PubMed Web of Science ®Google Scholar
• Forman S J, O'Donnell M R, Nademanee A P, Snyder D S, Bierman P J, Schmidt G M, et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987; 70: 587–588
   PubMed Web of Science ®Google Scholar
• Barrett A J, Horowitz M M, Ash R C, Atkinson K, Gale R P, Goldman J M, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79: 3067–3070
   PubMed Web of Science ®Google Scholar
• Chao N J, Blume K G, Forman S J, Snyder D S. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85: 3353–3354
   PubMed Web of Science ®Google Scholar
• Snyder D S, Nademanee A P, O'Donnell M R, Parker P M, Stein A S, Margolin K, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999; 13: 2053–2058
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Prentice H G, Durrant J, Franklin I M, Harrison G, Richards S M, et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993. Blood 2001; 98: 856a
   Web of Science ®Google Scholar
• Martin T G, Gajewski J L. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 2001; 15: 97–120
   PubMed Web of Science ®Google Scholar
• Cornelissen J J, Carston M, Kollman C, King R, Dekker A W, Löwenberg B, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572–1577
   PubMed Web of Science ®Google Scholar
• Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867–872
   PubMed Web of Science ®Google Scholar
• Esperou H, Boiron J M, Cayuela J M, Blanchet O, Kuentz M, Jouet J P, et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003; 31: 909–918
   PubMed Web of Science ®Google Scholar
• Martin H, Atta J, Bruecher J, Elsner S, Schardt C, Stadler M, et al. In patients with Bcr-Abl-positive ALL in CR, peripheral blood contains less residual disease than bone marrow: implications for autologous BMT. Ann Haematol 1994; 68: 85–87
   PubMed Web of Science ®Google Scholar
• Houot R, Tavernier E, Le Q H, Lhéritier V, Thiebaut A, Thomas X. Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology 2004; 9: 369–376
   PubMedGoogle Scholar
• Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi C L, Law N, Stover D, Ohno-Jones S, Druker B J, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145
   PubMed Web of Science ®Google Scholar
• Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Reiffers J, Silvert R T, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Scheuring U, Klein S A, Gökbuget N, Binckebanck A, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL. Leukemia 2002; 16: 2358–2365
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Hofmann W K, Komor M, Scheuring U, Brück P, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003; 9: 4674–4681
   PubMed Web of Science ®Google Scholar
• Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• Avramis I A, Laug W E, Sausville E A, Laug W E, Gonzalez-Gomez I, McNamara G, et al. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol 2003; 52: 307–318
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, Cortes J, O'Brien S, Giles F J, Kornblau S M, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396–4407
   PubMed Web of Science ®Google Scholar
• Thomas D A, Kantarjian H M, Cortes J, Faderl S, Giles F, Garcia-Manero G, et al. Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL. Blood 2006; 108: 87a–88a
   Web of Science ®Google Scholar
• Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed Bcr-Abl-positive acute lymphoblastic leukemia. Blood 2004; 104: 3507–3512
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed Bcr-Abl-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460–466
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, Beelen D W, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL. Blood 2006; 108: 1469–1477
   PubMed Web of Science ®Google Scholar
• Fielding A K, Richards S M, Lazarus H M, Litzow M R, Luger S M, Marks D I, et al. Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. Blood 2007; 110: 10a
   Web of Science ®Google Scholar
• De Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408–1413
   PubMed Web of Science ®Google Scholar
• Lee S, Kim D W, Kim Y J, Chung N G, Kim Y L, Hwang J Y, et al. Minimal residual disease-based role of imatinib as first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2003; 102: 3068–3070
   PubMed Web of Science ®Google Scholar
• Lee S, Kim Y J, Min C K, Kim H J, Eom K S, Kim D W, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449–3457
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, Bornhäuser M, Bug G, Scheuring U J, et al. Early molecular response to posttransplantation imatinib determines outcome in MDR+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL. Blood 2005; 106: 458–463
   PubMed Web of Science ®Google Scholar
• Anderlini P, Sheth S, Hicks K, Ippoliti C, Giralt S, Champlin R E, et al. Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 883–884
   PubMed Web of Science ®Google Scholar
• Carpenter P A, Snyder D S, Flowers M E, Sanders J E, Gooley T A, Martin P J, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791–2793
   PubMed Web of Science ®Google Scholar
• Visani G, Isidori A, Malagola M, Alberti D, Capdeville R, Martinelli G, et al. Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed p190 Bcr-Abl positive acute lymphoblastic leukemia. Leukemia 2002; 16: 2159–2160
   PubMed Web of Science ®Google Scholar
• Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Käbisch A, Lübbert M, et al. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia 2003; 17: 1919–1924
   PubMed Web of Science ®Google Scholar
• Rousselot P, Recher C, Buzyn A, Witz F, Vey N, Escoffre-Barbe M, et al. Results of the AFR07 prospective study in de novo Philadelphia positive ALL patients aged over 55 years: efficacy and safety of a Glivec® based induction followed by maintenance therapy with Glivec® and Pegasys®. Blood 2007; 110: 828A–829A
   Web of Science ®Google Scholar
• Delannoy A, Delabesse E, Lhéritier V, Castaigne S, Rigal-Huguet F, Raffoux E, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20: 1526–1532
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondi F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676–3678
   PubMed Web of Science ®Google Scholar
• Ottmann O G, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL. Cancer 2007; 109: 2068–2076
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of Bcr-Abl frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL. Blood 2007; 110: 727–734
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark R E, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745
   PubMed Web of Science ®Google Scholar
• Hofmann W K, Komor M, Hoelzer D, Ottmann O G. Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004; 45: 655–660
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Gallick G, Lin H, Arlinghaus R, , Bcr-Abl independence, et al. LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec. Leukemia 2003; 17: 829–838
   PubMed Web of Science ®Google Scholar
• Blencke S, Zech B, Engkvisto O, Greff Z, Orfi L, Horvath Z, et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004; 11: 691–701
   PubMedGoogle Scholar
• Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for Bcr-Abl1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453–461
   PubMed Web of Science ®Google Scholar
• Shah N P, Tran C, Lee F Y, Chen P, Norris D, Sawyers C L, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P W, Breitenstein W, Bruggen J, Cowan-Jacob S W, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141
   PubMed Web of Science ®Google Scholar
• Wild R, Castaneda S, Flefleh C, Fager K, Inigo I, Kan D, et al. BMS-354825, a dual SRC/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth. Blood 2004; 104: 549a
   Web of Science ®Google Scholar
• Talpaz M, Shah N P, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson R A, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110: 2309–2315
   PubMed Web of Science ®Google Scholar
• Porkka K, Simonsson B, Dombret H, Martinelli G, Ottmann O G, Zhu C, et al. Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015. Blood 2007; 110: 826A–827A
   Web of Science ®Google Scholar
• Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Brown D, et al. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or Bcr-Abl positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB. Blood 2007; 110: 828A
   Web of Science ®Google Scholar
• Foa R, Vignetti M, Vitale A, Meloni G, Guarini A, De Propris M, et al. Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205. Blood 2007; 110: 10a
   Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551
   PubMed Web of Science ®Google Scholar
• Ottmann O G, Larson R A, Kantarjian H M, Le Coutre P, Baccarani M, Haque A, et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood 2007; 110: 828A
   Web of Science ®Google Scholar
• Kantarjian H M, Cortes J, Le Coutre P, Nagler A, Pinilla J, Hochhaus A, et al. A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 2007; 110: 144a
   Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, Martinelli G, Baccarani M, Fischer T, et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL. Blood 2007; 110: 146a
   Web of Science ®Google Scholar
• Soverini S, Gnani A, Colarossi S, Castagnetti F, Palandri F, Giannoulia P, et al. Philadelphia chromosome-positive leukemia patients who harbor imatinib-resistant mutations have a higher likelihood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors. Blood 2007; 110: 101a
   Web of Science ®Google Scholar
• Harrington E A, Bebbington D, Moore J, Rasmussen R K, Ajose-Adeogun A O, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262–267
   PubMed Web of Science ®Google Scholar
• Giles F J, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman S J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I Bcr-Abl mutation. Blood 2007; 109: 500–502
   PubMed Web of Science ®Google Scholar
• De Lavallade H, Khorashad J S, Davis H P, Milojkovic D, Kaeda J S, Goldman J M, et al. Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I Bcr-Abl mutation. Blood 2007; 110: 2779–2780
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303–1312
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Oaks J J, Eiring A M, Notari M, Blaser B W, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Invest 2007; 117: 2408–2421
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters D K, Stoffregen E P, Jia T, Manley P W, Mestan J, et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005; 11: 6987–6993
   PubMed Web of Science ®Google Scholar
• Hoover R R, Mahon F X, Melo J V, Davey G O. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068–1071
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Wang Y, O'Brien S M, Faderl S H, Harris D M, Van Q, et al. The synthetic heat shock protein (hsp) 90 inhibitor EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome(Ph)-positive acute lymphoblastic leukemia (ALL) cells. Blood 2007; 110: 819A
   Web of Science ®Google Scholar
• Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 2002; 21: 5868–5876
   Google Scholar